Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

After UK Cancelled Order, EU Could Provide Lifeline

Executive Summary

Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.

You may also be interested in...



Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs

Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.

UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back

The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.

Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer

Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel